Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

A review of BB Biotech’s portfolio and results for 2024 as well as the outlook for 2025 will be included in the Annual Report, to be published on February 21, 2025. The figures and information ...

After hours: January 23 at 5:42:54 PM EST ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

BB Biotech AG reports preliminary full-year 2024 results with a net profit of CHF 76 mn, proposing a dividend of CHF 1.80 per share at the AGM on March 19, 2025, focusing on shareholder returns and bi ...